Thus, BTK inhibitors such as ibrutinib are used in relapse/refractory MCL patients with good initial response 98 and the benefit of BTK inhibitors use earlier in the treatment course is under investigation with encouraging results 8,99-102. Here, BTK is linked to mantle cell lymphoma.